It WAS known that Momenta would have to reimburse Sandoz for development costs upon approval of m-enox. (In fact this had been discussed on this board for weeks in advance of the approval announcement)
The specific formula for reimbursement (capped at 50% of revenue per quarter) was not known. MNTA coming out and explicitly noting that they expect to fully reimburse Sandoz in 3 quarters is also a new tidbit of information.
In light of the above, your assertion that the market sold MNTA off because of this news is without merit.
It was public that they had to repay a certain amount, the amount wasn't known.
$40M (my est) isn't much. I think it will be repaid within 2 quarters. I don't consider it a big deal since it's non recourse debt and will be repaid quickly.
What happens with Teva is obviously irrelevant to the debt. If Teva were approved soon, tack on a year. If not, I suspect it may be gone by the end of the year.
Market Data 
Markets 
AI
